Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) on Tuesday, setting a price target of $35, which is approximately 85.77% above the present share price of $18.84.
Schwartz expects Aurinia Pharmaceuticals to post earnings per share (EPS) of -$0.39 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Aurinia Pharmaceuticals, with an average price target of $33.
The analysts price targets range from a high of $40 to a low of $23.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $14.67 million and a net profit of -$50.35 million. The company's market cap is $2.44 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.